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Abstract
The concept that the intestine and chronic kidney disease inﬂuence each other, emerged only
recently. The problem is multifaceted and bidirectional. On one hand, the composition of the intes-
tinal microbiota impacts uraemic retention solute production, resulting in the generation of essen-
tially protein-bound uraemic toxins with strong biological impact such as vascular damage and
progression of kidney failure. On the other hand, the uraemic status affects the composition of in-
testinal microbiota, the generation of uraemic retention solutes and their precursors and causes
disturbances in the protective epithelial barrier of the intestine and the translocation of intestinal
microbiota into the body. All these elements together contribute to the disruption of the metabolic
equilibrium and homeostasis typical to uraemia. Several measures with putative impact on intes-
tinal status have recently been tested for their inﬂuence on the generation or concentration of
uraemic toxins. These include dietary measures, prebiotics, probiotics, synbiotics and intestinal
sorbents. Unfortunately, the quality and the evidence base of many of these studies are debatable,
especially in uraemia, and often results within one study or among studies are contradictory.
Nevertheless, intestinal uraemic metabolite generation remains an interesting target to obtain in
the future as an alternative or additive to dialysis to decrease uraemic toxin generation. In the
present review, we aim to summarize (i) the role of the intestine in uraemia by producing uraemic
toxins and by generating pathophysiologically relevant changes, (ii) the role of uraemia in modify-
ing intestinal physiology and (iii) the therapeutic options that could help to modify these effects
and the studies that have assessed the impact of these therapies.
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Introduction: the intestine in health and disease
The previous view that the gut is a largely inert organ has
been challenged for more than a decade, as intestinal
microbiota provide essential functions which the human
body by itself is unable to supply [1], such as the harvest-
ing of essential food products, energy saving, metabolism
of xenobiotics, protection against invasion by alien mi-
crobes, renewal of the intestinal epithelium, generation of
vitamins and balancing of immune function [1, 2].
The deﬁnition of the ‘normal’microbiome with its striking
inter-individual differences, sometimes due to day-by-day
elements such as diet or exercise [3, 4], raised the obvious
question about what happens during disease [5, 6]. Already
in 2003, intestinal microbiome changes were described for
multi-organ failure, colon cancer and inﬂammatory bowel
disease [2]. In the last decade, this list was completed by a
long series of highly prevalent chronic diseases. The relation
between liver disease and gut microbiome could be ex-
pected by their juxtaposition [7]. However, also a link was
demonstrated, as cause or consequence, with diabetesmel-
litus, obesity, insulin resistance, the metabolic syndrome,
ageing, micro-inﬂammation and cardiovascular disease
[6, 8, 9].
The awareness that also chronic kidney disease (CKD) is
related to the intestinal status came relatively late [10]
and stemmed in part from the insight that several toxins
active in the uraemic syndrome originate from the intes-
tine [11, 12].
Many of the above-mentioned chronic conditions linked
to changes in the gut microbiome are also associated with
renal failure or are considered as a cause of it. The ques-
tion has been raised whether the gut microbiome might
be one of the common denominators linking all these ele-
ments together [13, 14]. It could be possible that some of
the solutes generated in the gut and currently called
uraemic toxins exert their toxicity even with normally
functioning kidneys [15] and thus are not only uraemic
toxins but toxins in general. This hypothesis, however,
remains to be conﬁrmed.
Thus, there are good reasons to take a close look at the
interaction between the gut and kidneys, especially since
understanding the mechanisms might create opportun-
ities to develop novel targeted therapeutic interventions
[13, 16]. In this narrative review, we will consider the
current state of the art on this topic, including the bidirec-
tional interaction between gut and uraemic toxicity, a
proof of concept of the role of the intestine in uraemic
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toxin generation, the evidence of the toxicity of the gener-
ated molecules and a comprehensive review of the avail-
able therapeutic options, considering uraemic toxicity/
toxins as key elements.
The bidirectional interference between the gut
and uraemia
The gut is responsible for the generation of uraemic reten-
tion compounds with pathophysiologic impact, whereas
uraemia as such causes structural and functional intes-
tinal changes which indirectly cause morbidity and mor-
tality [17] by inducing inﬂammation via diverse pathways
[10]. Thus, the crosstalk between uraemia and the intestine
is based on two different elements, but the consequences
are the same, based on a double effect: induction of micro-
inﬂammation going along with an incompetence of the
pre-activated immune system to cope with stimuli [10, 18],
resulting in an enhanced risk of infection which at the end
in its turn again is pro-inﬂammatory. Inﬂammation remains
one of the major causes of complications and death in CKD
but also in non-CKD conditions.
The gut as a source of uraemic toxins
Uraemic toxins are generated in several ways (Figure 1):
(i) some of them (e.g. peptides) are produced in the body
without the contribution of the gut; (ii) others (e.g. the ad-
vanced glycation end products—AGEs) enter the body via
unmodiﬁed absorption of nutritional elements by the intes-
tine; (iii) ﬁnally, essentially protein-bound solutes such as
the phenols, indoles or hippurates but also trimethylamine
oxide (TMAO) are generated metabolically from precursors
originating from microbial fermentation [12, 19]. A number
of retention solutes (e.g. AGEs, uric acid) originate partially
in the intestine and partially in the body.
The active role of the intestine is especially prominent in
the generation of the protein-bound uraemic toxins (e.g.
indoxyl sulphate and p-cresyl sulphate) (Figure 1, path-
ways B and C). At the origin are amino acids (in casu tryp-
tophan and tyrosine) resulting from the digestion of
proteins that are transformed by the intestinal microbiota
into precursors of uraemic toxins like indole and p-cresol).
Those are then conjugated during absorption in the intes-
tinal wall or further downstream in the liver before their
transfer into the systemic circulation [12]. The most abun-
dant conjugates are the sulphates although many other
structural variants are possible (Table 1). In addition, func-
tional groups, such as methyl or hydroxyl, may be added
in different positions. Some compounds remain unmodi-
ﬁed (e.g. kynurenine).
Additional contributing factors
In uraemia, a number of further intestinal modiﬁcations
involved in the so-called assimilation process cause an
increase in the generation of uraemic toxins compared
with the normal condition. First, amino acids, if less well
absorbed along the gastrointestinal tract, present more
substrate to the intestine for microbial metabolism [12].
Second, the balance of intestinal microbiota is shifted in
favour of proteolytic microorganisms producing more toxin
precursor by fermentation (see below) [20–22]. Finally, ab-
normal intestinal motility prolonging colon transit [23, 24]
deprives the colon from carbohydrates inducing upstream
expansion of proteolytic species increasing generation of
bacterial toxins and increasing time for their absorption
[23]. In an elegant study, Bammens et al. assessed the
urinary excretion of p-cresol, the precursor of cresyl conju-
gates and a surrogate of their generation: approximately
twice as much p-cresol was excreted per 24 h in the urine
of advanced CKD patients than that of controls with normal
kidney function, and urinary p-cresol excretion was nega-
tively correlated with GFR [25].
It is an upside-down world: changes of the intestine
due to uraemia
The intestine does not only play a role in the generation
of uraemic toxins, but also the other way around uraemia
Fig. 1. Main metabolic pathways involved in uraemic toxin generation. (A)
ingestion via the gastrointestinal tract and direct unmodiﬁed uptake via
the intestinal wall into the systemic circulation (e.g. advanced glycation
end products); (B) gastrointestinal uptake of a precursor (e.g. an amino
acid), that is transformed by the intestinal microbiota into another
precursor (e.g. indole); after its uptake via the intestinal wall and portal
vein, this precursor is further conjugated by the liver (e.g. indoxyl sulphate)
before its transfer into the systemic circulation; (C) gastrointestinal uptake
of a precursor (e.g. an amino acid), that is transformed by the intestinal
microbiota into another precursor (e.g. indole); the precursor is conjugated
during its uptake via the intestinal wall (e.g. indoxyl sulphate) and then
passes into the systemic circulation via the liver without further
modiﬁcation; (D) endogenous generation without contribution of the gastro-
intestinal tract (e.g. β2-microglobulin). Modiﬁed from Schepers et al. [12].
Table 1. Precursors and conjugates composing intestinally generated
uraemic metabolitesa
Precursors
Indole
Phenol
Cresol
Hippurate
Methylamine
Conjugates
Sulphate
Lactate
Acetate
Glucuronide
Propionate
Acetylglycine
Propionylglycine
Oxide
aThe list is not exhaustive.
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(and by extension uraemic toxins) may cause functional
and structural modiﬁcations in the intestine with patho-
physiologic consequences.
First, bacterial species that are prone to generate
uraemic toxins by fermentation are privileged in uraemia
(Table 2) and outnumber protective species such as lacto-
bacilli [20, 21]. Up till now, only three studies compared
the composition of the intestinal microbiota of uraemic
versus control patients by bacterial genomic analysis:
all found a disbalance in the proportional distribution of
intestinal bacteria with a predominance of species with a
pathologic impact and/or a shortage of those having no
deleterious effect [21, 26, 27], identical to what had been
demonstrated before in uraemic rats [26]. Earlier studies
using non-genomic techniques had also deﬁned that a
number of bacterial species prone to proteolytic fermen-
tation, among which the clostridia species, were more
abundant [20].
Second, colon bacteria in uraemia tend to move to sec-
tions of the body where they normally are not present
unless in very low quantities (translocation). This includes
migration of microbes into the jejunum [23], into the mes-
enteric lymph nodes and further downstream into the
blood and the rest of the body [22, 28–31]. Bossola et al.
found bacterial-derived DNA fragments in the blood of
haemodialysis patients, but since bacteria were also de-
tected in dialysate, an extra-intestinal source, i.e. con-
taminated dialysate, could not be excluded [28]. However,
Wang et al. reported similar ﬁndings in non-dialysed CKD
patients, pointing to the fact that also sources other than
dialysate can be responsible for these DNA fragments
in uraemic patients, and in this case, the intestine is a
primary candidate culprit [22]. More convincingly even,
all bacterial DNA found in the blood was the same as that
from genera present in the gut [22]. In uraemic rats, bac-
terial DNA of enteric species was demonstrated in the
mesenteric lymph nodes, blood and even in liver and
spleen [30]. Both in humans and in animals, this bacterial
overgrowth and translocation was associated to micro-
inﬂammation [22, 30].
Third, compelling arguments favour a loss of the intestinal
protective barrier in uraemia. After the ﬁrst results in this dir-
ection published in 1991 [32], Vaziri and co-workers demon-
strated in vitro and ex vivo that the uraemic milieu disrupted
intestinal epithelial protection [21, 33] by depleting protein
constituents of the tight junctions (Zona Occludens-1 (ZO-1),
Claudin-1 and Occludin). The ensuing leakage could cause
inﬂammation by propagating endotoxin transfer into the
bloodstream. Vaziri et al. could also demonstrate that urea
created the same effect [34], with a further enhancement
by adding urease, suggesting that urease producing bac-
teria generating ammonia amplify this effect [34]. The
same authors also demonstrated that the administration
of the sorbent AST-120 (KremezinR) protected the intes-
tinal barrier in uraemic rats [35]. As AST-120 is essentially
known for decreasing the concentration of protein-bound
uraemic solutes rather than that of urea, it can reasonably
be assumed that also other uraemic solutes than urea
[36], or their precursors, disrupt the intestinal barrier.
Thus, in summary, uraemia causes a series of intestinal
changes (bacterial translocation, leakiness of the intes-
tinal barrier and the generation of protein-bound uraemic
toxins) that all lead to inﬂammation, a major cause of
morbidity and mortality, both in CKD and the non-CKD
population.
Proof of concept
The theory that intestinal microbiota contribute to uraemic
toxin generation by metabolizing breakdown products
derived from dietary protein intake was conﬁrmed in a
number of proof-of-concept studies.
In 1965, Einheber and Carter demonstrated that germ-
free rats made anephric survived longer and lost less
weight than their counterparts with intestinal microorgan-
isms [37]. In 1982, Yokoyama et al. demonstrated that
sterilizing the intestine by a combination of antibiotics in
weanling pigs with normal kidneys decreased the faecal
and urinary excretion of phenolic and aromatic bacterial
metabolites and increased their body weight [38]. A recent
study demonstrated that antibiotic prophlaxis for episodes
of neutropenia in patients having received an allogeneic
stem cell transplantation resulted in a shift of intestinal
microbiota and in a dramatic decrease of urinary indoxyl
sulphate concentration [39].
Recently, Wikoff et al. compared by untargetedmetabolo-
mic mass spectrometry the plasma from germ-free mice
with normal kidney function with that of animals with
normal faecal microbiota and could indicate a number of
discriminators, among which are several compounds known
as protein-bound uraemic toxins such as indoxyl sulphate,
hippuric acid and phenylacetic acid [40], which are also a
substrate of renal tubular organic anion transporters (OATs)
explaining their retention in kidney failure if the tubules are
damaged [41].
Aronov et al. applied metabolomic analysis by mass
spectrometry to compare concentration of plasma solutes
of six haemodialysis patients without a colon, to that of
nine patients with a colon [42], with as aim the identiﬁca-
tion of metabolites discriminating between these two
groups. Among the 30 discriminators were several protein-
bound uraemic retention products. In most cases, a ratio of
plasma concentrations of <0.05 for those without versus
with colon was found; for p-cresyl sulphate, the ratio was
even 0.01 [42], indicating that concentration was ∼100
times higher in patients with a colon.
Patel et al. found in healthy vegetarians a strikingly lower
urinary excretion of indoxyl sulphate and p-cresyl sulphate,
as equivalents of their intestinal generation, than that in
subjects with a more conventional food intake [43]. A similar
study of >20 years before had shown lower serum concen-
trations and faecal losses of phenol and p-cresol in veganists
[44]. Increasing dietary ﬁbre intake by administration of re-
sistant starch for 6 weeks in a randomized controlled trial
Table 2. Fermenting intestinal bacterial speciesa
Clostridia
Clostridium bifermentans
Clostridium sporogenes
Clostridium clostridiforme
Clostridium leptum
Peptostreptococcus asaccholyticus
Peptostreptococcus indolicus
Bacteroidetes
Bacteroides thetalotaomicron
Bacteroides putredinis
Other
Fusobacterium nucleatum
Actinomyces israelii
Megalosfaera elsdinii
Propionibacterium acnes
aBased on Smith and MacFarlane [20].
The intestine and the kidneys 3
 at G
hent U
niversity on February 24, 2016
http://ckj.oxfordjournals.org/
D
ow
nloaded from
 
(RCT) in haemodialysis patients decreased plasma-free
indoxyl sulphate whereas there was a trend for a decrease
of free p-cresyl sulphate [45].
Eloot et al. assessed the relationship between the pre-
dialysis concentration of several essentially protein-bound
uraemic toxins and a number of potential inﬂuencing
factors such as Kt/Vurea as an index of dialysis adequacy,
normalized protein catabolic rate (nPCR) as an index of
dietary protein intake, residual renal function, age, dia-
betes, gender, body weight and dialysis vintage [46]. A
correlation was found, essentially for residual renal func-
tion and nPCR, and not for the other factors, including
Kt/Vurea, again suggesting a role for digestion of dietary
proteins in uraemic toxin generation and concentration,
even overruling the impact of dialysis adequacy.
Toxicity of the compounds of intestinal origin
The toxicity of the protein-bound solutes, which compose
a large fraction of the intestinally generated compounds,
remains a matter of debate, as in many experimental
studies too high concentrations resulted in an overesti-
mation of potential toxicity [47]. In analogy with drugs,
such toxicity should reasonably be exerted by the free,
unbound fraction. A recent systematic review, however, un-
ravelled 27 studies where correct free concentrations of two
prototypic protein-bound solutes, p-cresyl sulphate and
indoxyl sulphate, had been applied [48]. Interference was
shown with several key metabolic processes involved in the
uraemic syndrome, such as reactive oxygen species gener-
ation, endothelial dysfunction, epithelial-to-mesenchymal
transition, leukocyte–endothelial interaction, deterioration
of cardiac cell functional capacity, renal tubular cell senes-
cence, expression of tissue factor and sensitivity to insulin.
These data refer to the core of the morbidity and mortality
of uraemia, i.e. cardiovascular disease and progression of
renal failure. Together with observational studies showing
a highly signiﬁcant association between concentration of
protein-bound toxins with hard endpoints such as cardio-
vascular events, progression of renal failure and mortality
[49–54], these data offer strong arguments in favour of a
key role of indoxyl sulphate and p-cresyl sulphate in the
uraemic syndrome.
Without following the same rigid approach as applied in
the systematic reviewmentioned [48], we found at least ﬁve
more recent publications conforming the inclusion criteria
of the latter study, covering inhibition of drug metabolism
[55]; increased crosstalk between leukocytes and endothe-
lium, glycocalyx degradation and vascular leakage [56];
apoptosis of osteoblasts [57]; induction of tubular endothe-
lial growth factor receptor leading to tissue remodelling [58]
and inhibition of breakdown of angiotensin II [59].
Similar effects were also described for other protein-
bound toxins [60] such as hippuric acid [61–63], indole
acetic acid [61, 62, 64–67], phenyl acetic acid [61, 67, 68];
p-cresylglucuronide [56, 67, 69] and kynurenic acid [61,
67] (Table 3).
The link of AGEs with inﬂammation has been empha-
sized before [70]. Nutritional AGEs contribute to this effect
since AGE-rich food administered to diabetics increased
endothelial free radical production and decreased arterial
responsiveness to vasodilatory stimuli [71].
Several arguments thus plead in favour of a broad array
of biological effects exerted by uraemic solutes of intes-
tinal origin, and it seems rational to explore novel strat-
egies to decrease their concentration, especially since
removal even with the most efﬁcient dialysis strategies is
deceiving.
Therapeutic options
Several approaches have the potential to decrease the
capacity of intestinal microbiota to generate uraemic
solutes and their precursors (Table 4) [12, 72]. Following
hypothesis-generating experimental studies, several clin-
ical studies have recently resulted in a few reviews expres-
sing an afﬁrmative opinion about such therapies [13, 14,
16]. However, those clinical studies are to be checked
critically with regard to their evidence base, with an in-
creasing order of importance given to (i) uncontrolled con-
centration studies in the normal population, (ii)
uncontrolled concentration studies in uraemics, (iii) un-
controlled hard outcome trials, (iv) RCTs with toxin con-
centration as outcomes and (v) hard outcome RCTs
(Table 4).
Diet
With protein as the source of amino acids, decreasing
protein intake should diminish generation of uraemic re-
tention solutes. A shift from a vegetable to meat diet in
healthy subjects indeed impacts the intestinal balance of
microbiota [4] and increases urinary excretion of phenols
and ammonia [109]. Veganistic and vegetarian diets in
non-uraemic populations decrease the concentration and
generation of protein-bound uraemic solutes or their
precursors [43, 44] but remain a matter of concern in the
malnourished uraemic population. Although low-protein
diet has a nephroprotective effect, it should be taken into
account that a large section of CKD patients, not even on
dialysis, suffer from protein malnourishment. On the other
hand, what is currently a standard diet in Western coun-
tries often contains excessive quantities of protein.
Selective diets excluding the sources of speciﬁc toxins
are an alternative. When AGE-rich food was administered
to both non-uraemic and uraemic diabetics, AGE concen-
tration and cross-linking in plasma increased compared
Table 3. Protein-bound uraemic toxins other than indoxyl sulphate
and p-cresyl sulphate with toxic impacta
Affected biological function Toxic solute
Protein binding of drugs [63] Hippuric acid
Expression of drug transporters [62] Hippuric acid
Indole acetic acid
Renal tubular efﬂux pumps [61] Hippuric acid
Indole acetic acid
Phenyl acetic acid
Kynurenic acid
Tissue factor expression [64, 66] Indole acetic acid
Glucuronidation [67] Indole acetic acid
Phenyl acetic acid
Kynurenic acid
Mitochondrial metabolism [67] Indole acetic acid
Phenyl acetic acid
P-cresyl glucuronide
Nitric oxide synthase [68] Phenyl acetic acid
Leukocyte-free radical production [69] P-cresyl glucuronideb
Endothelial albumin leakage [56] P-cresyl glucuronideb
Endothelial Cox-2 mRNA expression [65] Indole acetic acid
aList is not exhaustive.
bIn combination with p-cresyl sulphate.
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Table 4. Summary of studies on therapeutic options affecting uraemic toxin concentration/generation via intestinal pathways in humans
Uncontrolled RCT
Concentration
Outcomes
Concentration
Outcomes
Intervention Target molecule Healthy Uraemia Uraemia Healthy Uraemia Uraemia
Diet
Vegetable/vegetarian [43, 44] PBUT +
Phenols +
Phosphate +
AGE-free diet [19] AGE + +
Oxalate-controlling diet [73] Oxalate +
Prebiotics
Resistant starch [45, 74] Phenols +
Ammonia +
IS +
pCS −
Inulin [75] p-Cresola +
Phenol −
Lactulose [76] p-Cresol +
OF-IN [76–79] p-Cresol + +
pCS +
IS −
AXOS [80] p-Cresol +/−b
Phenol −
Arabinogalactan [81] Creatinine −
Urea +
Isphagula husk [81] Creatinine −
Urea +
Gum Arabic supplement [82] Creatinine −
Urea +
Fermentable carbohydrate [83] Urea +
probiotics
L. casei Shirota [77, 78, 84] Urea +/−c
Creatinine −
p-Cresol +
L. acidophilus, B. longum, S. thermophilus, enteric coated [85] Urea +
Creatinine −
Uric acid −
B. breve [77, 78] p-Cresol +
Lebenin® [86] IS +
Phenol −
p-Cresol −
Biﬁdobacteria, gastro-resistant capsule [87–89] IS +d −/+e
Hcy +
Renadyl® [90] IS − −f
IG −
pCS −
pCG −
Pentosidine −
Β2-M −
Oxalobacter formigenes [91] Oxalate +
Lactic acid bacteria [73, 92–95] Oxalate +/±/− −
(continued )
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Table 4. Continued
Uncontrolled RCT
Concentration
Outcomes
Concentration
Outcomes
Intervention Target molecule Healthy Uraemia Uraemia Healthy Uraemia Uraemia
Synbiotics
L. casei, B. breve, galacto-oligosachharides [96] p-Cresol +
phenol −
IS −
L. casei Shirota, OF-IN [78] p-Cresol +
Probinul-neutro® [97] p-Cresol +
Prebiotic–probiotic mixture [98] +g
AKSB [73] oxalate −
Sorbents
Sevelamer [99, 100] Oxalate −
PBUT −
AST-120 [101–106] PBUT + + +/−h
Chitosan [107] IS + +i
Phosphate +
Others
Acarbose [108] p-Cresol +
The plus symbols indicate that the study has a positive impact; thus in general a decrease in concentration or generation or a protective effect against morbidity; the negative symbols indicate that there was no
impact; plus or minus symbols indicate contradictory results; blank spaces indicate that no valid data were found to include in the table.
PBUT, protein-bound uraemic toxins; AGEs, advanced glycation end products; pCS, p-cresyl sulphate; pCG, p-cresyl glucuronide; IS, indoxyl sulphate; IG, indoxyl glucuronide; β2-M, β2-microglobulin; Hcy, homocysteine;
OF-IN, oligofructose-enriched inulin; AXOS, arabinoxylan-oligosaccharides; Lebenin®, antibiotic-resistant Biﬁdobacterium infantis, Lactobacillus acidophilus, Enterococcus fecalis; Renadyl®, Streptococcus thermophilus,
L. acidophilus, B. longum; Probinul-neutroR, mixture of several Lactobacilli and Biﬁdobacteria, S. thermophilus, inulin and tapioca-resistant starch; AKSB, fructo-oligosaccharide, E. faecium, S. cerivisiae.
ap-cresol in all studies surrogate for p-cresyl sulphate + p-cresyl glucuronide.
bPositive after 2 weeks but negative after 3 weeks.
cPositive at high dose, negative at low dose, no statistical comparison between high and low dose.
dOnly if included in gastro-resistant capsule—not in powder formulation.
eOverall negative; only an inhibitory effect on CKD progression in the subgroup with the worst kidney function.
fInﬂammation and quality of life.
gDecline of eGFR.
hSmall Japanese randomized trials showed a beneﬁt on progression of CKD, which could, however, not be conﬁrmed in a large European–American RCT; one RCT showed an improved response to ESAs.
iOxidative stress parameters.
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with AGE-poor diet [19]. In the run-in phase of an RCT on
oxalate decreasing intervention in hyperoxaluria, a diet
controlling oxalate intake decreased urinary oxalate com-
pared with a free-choice diet [73].
Prebiotics
Prebiotics are non-digestible compounds improving the
composition and/or function of the intestinal microbiota
[110].
An animal study by Koppe et al. showed that CKD as
well as p-cresyl sulphate caused insulin resistance, distur-
bances of adipose tissue metabolism and reallocation
of fat throughout the body [111]. When arabinoxylan-
oligosaccharides (AXOS) were administered to CKD animals,
p-cresyl sulphate concentration decreased while insulin
sensitivity was restored [111]. In 5/6 nephrectomized rats,
galacto-oligosaccharides decreased caecal indoles and
serum indoxyl sulphate and improved renal injury, stress
markers and apoptosis [112].
In healthy humans, resistant starch decreased faecal
phenol and ammonia [74]. When assessing solute gener-
ation out of radiolabelled tyrosine, urinary excretion of
p-cresol was decreased by inulin [75]. A similar effect on
p-cresol was seen also for oligofructose-enriched inulin
(OF-IN) and lactulose [76], a ﬁnding conﬁrmed for OF-IN
in two RCTs [77, 78]. In another RCT assessing AXOS,
urinary p-cresol was decreased after 2 but not 3 weeks,
and no change was shown for phenol [80].
In uraemia, a few early studies only focused on the con-
centration of the water-soluble compounds creatinine
and/or urea [81–83,113]. In 1984, Rampton et al. studied
the effect of arabinogalactan and of Isphagula husk on
blood urea and creatinine [81]. The study contained no
control group, and no effect was seen on creatinine. The
therapeutic decrease in urea claimed by the authors is
doubtful in view of the far from stable baseline [81]. Bliss
et al. randomized non-dialysed CKD patients on low-protein
diet to gum Arabic supplement or placebo and found a de-
crease in urea concentration but not of creatinine, while
also nitrogen in stools increased [82]. In 2006, Younes et al.
conﬁrmed their earlier ﬁndings in animals [113] in men,
indicating a decrease of urea after administration of fer-
mentable carbohydrate supplements. The study, however,
contained no controls [83].
More recently, in a single-centre, non-randomized, open-
label study with an escalating dose of prebiotic over 4 weeks,
followed by a 4-week washout, OF-IN [79] has been
shown in maintenance haemodialysis patients to impact
plasma concentration of p-cresyl sulphate, but not of
indoxyl sulphate [79]. In an RCT in haemodialysis patients,
the administration of resistant starch decreased plasma-
free indoxyl sulphate [45]. The study was, however, char-
acterized by a substantial number of dropouts, both in the
control and the verum group (29%) [45].
Probiotics
Probiotics are living organisms, administered as food com-
ponents or supplements, which provide speciﬁc beneﬁts
by themselves, essentially by creating a more favourable
balance in the composition of intestinal microbiota [114].
Urea. Urease-expressing bacteria may decrease blood
urea. Most studies in this context are experimental, either
in vivo in rats after 5/6 nephrectomy or acetaminophen-
induced kidney failure or in vitro [115–117]. The probiotics
not only decreased urea but also other markers of kidney
failure like creatinine or oxidative stress, and they pro-
longed life span [116, 117]. In a rat study assessing ﬁve
different probiotic combinations, only two (one containing
Bacillus pasteuri and one Lactobacillus sporogenes) de-
creased BUN and serum creatinine [118]. A matter of
concern is that degradation of urea by urease probably
generates ammonia, which is now considered a uraemic
toxin by itself [119].
In an uncontrolled study in CKD 3-4, high-concentration
Lactobacillus casei Shirota (16 × 109 CFU/mL) but not low-
dose (8 × 109) decreased blood urea only while creatinine
remained unmodiﬁed [84]. The decrease of urea was only
by 11%.
In an RCT assessing in CKD patients, the effect of an
enteric-coated probiotic combination of Lactobacillus acid-
ophilus, Biﬁdobacterium longum and Streptococcus thermo-
philus on the evolution of BUN, serum creatinine and uric
acid, only a borderline signiﬁcant decrease in BUN could
be observed, which remained absent in close to 40% of
subjects [85].
Protein-bound uraemic toxins. Essentially lactic acid bac-
teria including Lactobacilli and Biﬁdobacteria have been
studied.
In two placebo-controlled RCTs in healthy subjects,
Lactobacillus casei Shirota and Biﬁdobacterium breve both
reduced urinary p-cresol in the urine after 4 weeks [77, 78].
In haemodialysis patients, Lebenin®, a mixture of anti-
biotic-resistant lactic acid bacteria, resulted in a decrease
in plasma indoxyl sulphate but not in phenol and p-cresol
[86]. In a study by Takayama et al., Biﬁdobacterium in a
gastro-resistant capsule but not in powder formulation de-
creased indoxyl sulphate in haemodialysis patients [87].
The same encapsulated variant also decreased homocys-
teinemia and increased serum folate [88]. None of these
studies, however, checked hard endpoints or were even
placebo controlled. The study by Takayama et al. contained
a non-randomly selected group, treated with powdered Bi-
ﬁdobacterium without showing any effect [87]. This might
be considered as a sort of control, but, if true, these data
cast doubts on other studies with unencapsuled lactic acid
bacteria that were successful.
In an uncontrolled Japanese hard-endpoint study evalu-
ating an enteric capsule preparation of Biﬁdobacterium
longum, no effect was seen on progression of renal failure
[89]. An RCT in end-stage CKD patients studying Renadyl®
showed no differences in protein-bound uraemic toxin con-
centration nor in surrogate endpoints such as inﬂamma-
tory and quality-of-life parameters [90].
Oxalate. A speciﬁc area of interest is the research on
oxalate degrading bacteria, mostly in the context of oxalate
urolithiasis and of hyperoxaluria, either because of genetic
reasons or of medical predisposition (bowel disease). Of
note, apart from being a reason for CKD in extreme forms
of hyperoxaluria or because of kidney stones, oxalate is also
a uraemic retention compound by itself.
A number of uncontrolled clinical trials in subjects
without manifest renal failure with Oxalobacter formi-
genes or with lactic acid bacteria showed a decrease in
oxalate plasma concentration and/or generation [91,92],
but another uncontrolled trial with a mixture of lactic acid
bacteria gave contradictory results, with a decrease for
the lower but not for the higher dose [93]. Another
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uncontrolled study showed no effect al all [94], which was
also the case for two RCTs [73, 95].
Synbiotics
Synbiotics contain a mixture of prebiotics and probiotics.
In an uncontrolled study in HD patients, a preparation
combining Lactobacillus casei, Biﬁdobacterium breve and
galacto-oligosaccharides decreased p-cresol but not indoxyl
sulphate or phenol [96]. Patients with high p-cresol tended
to have defaecation difﬁculties, which were normalized
together with the decrease in p-cresol after 2 weeks of
symbiotic treatment.
In a crossover RCT in healthy subjects, co-administration
of Lactobacillus casei Shirota and OF-IN resulted in a re-
duction of urinary p-cresol excretion [78]. An RCT applying
Probinul-neutro® in CKD 3-4 showed a decrease of plasma
p-cresol versus baseline and placebo [97]. In placebo con-
trols, however, plasma p-cresol spontaneously rose by
>50% during a short follow-up of only 1 month [97], sug-
gesting unidentiﬁed confounders forcing the results to a
difference favouring synbiotics. A randomized open-label
trial allotting CKD 3-4 patients to either protein restrictive
diet alone or a combination of protein restriction, prebiotics
and probiotics, showed a slower decline of eGFR in patients
on the combined regimen [98]. A placebo-controlled RCT
with crossover after 4-week washout has recently been
developed to assess the effect on indoxyl sulphate and
p-cresyl sulphate next to cardiovascular risk parameters
and indices of renal damage, quality of life and gastro-
intestinal status [120].
Finally, in an RCTassessing next to diet and two prebiotic
formulations, also the symbiotic AKSB (fructo-oligosacchar-
ide, Enterococcus faecium and Saccharomyces cerivisiae) for
their effect on oxalate levels could show no effect [73].
Absorption
The possibility that orally administered sorbents could
remove uraemic solutes or their precursor by binding them
in the intestine has long since been recognized, but not
extensively explored. In fact, all phosphate binders are a
classical example of formulations capturing in the intestine
an actor associated with negative outcomes of uraemia.
One of the novel phosphate binders, sevelamer, absorbs
also other compounds such as cholesterol [121] and anti-
biotics [122]. It has been hypothesized to absorb oxalate,
but this could not be conﬁrmed in an open-label non-
randomized clinical trial [99]. Studies exploring the capacity
of sevelamer to absorb protein-bound uraemic solutes or
their precursors turned out negative, both in animals [123]
and in an RCT in haemodialysis patients [100].
Probably the most successful results in the context of
intestinal absorption have been obtained with the sorbent
AST-120, which in a randomized trial dose-dependently
decreased plasma indoxyl sulphate [101], while also other
protein-bound compounds are likely to be removed by
AST-120 [124]. Protein-bound compounds have been as-
sociated in both experimental [48] and clinical studies
[53] to progression of CKD. Animal studies and retrospect-
ive clinical studies have suggested a nephroprotective effect
for AST-120 [125, 126], which was conﬁrmed in a number
of small Japanese RCTs [102–104]. A subsequent large RCT
in the USA and Europe could, however, not conﬁrm those
ﬁndings [105]. In a recent animal study, AST-120 protected
against cardiorenal ﬁbrosis subsequent to myocardial in-
farction [127]. In an RCT, AST-120 potentiated the activity of
erythropiesis-stimulating agents (ESAs) in stage 5 CKD pa-
tients [106].
In an uncontrolled longitudinal follow-up study in
haemodialysis patients, a decrease of indoxyl sulphate,
phosphate and oxidative stress parameters versus base-
line was seen with the sorbent chitosan [107].
Other interventions
Oral administration of sulfotransferase inhibitors to rats
with acute renal failure suppressed indoxyl sulphate accu-
mulation and had a positive effect on kidney function [128].
This study, however, raises the question of what happens to
the mother compound p-cresol if it is not sulphated. Either
it may exert its own toxicity [129], or it may be metabolized
into the other main conjugate p-cresylglucuronide, which
also has biological effects on its own [69]. Also meclofena-
mate strongly inhibited hepatic generation of indoxyl sul-
phate and had a nephroprotective effect [130]. In human
volunteers, acarbose, an α-glucosidase inhibitor increasing
colonic availability of carbohydrates, decreased urinary
p-cresol excretion [108].
Summary of interventional studies
A dietary approach by restricting protein intake helps redu-
cing the generation of uraemic toxins. Of note, protein re-
striction has been considered for a long time as
nephroprotective [131], while at the same time reducing the
generation of protein-bound uraemic toxins which are likely
to play a role in progression of kidney failure. Nevertheless,
in view of the possible link to malnutrition, such regimes
should be tested in controlled studies, before they really can
be considered of clinical value in uraemia. Keto-analogues
may neutralize the negative impact of protein intake, but
their effect on uraemic toxins has not yet been studied.
Prebiotics, probiotics and synbiotics could play a role in
reducing the generation of uraemic toxins, but the results
of clinical studies have been deceiving, with sometimes
contradictory results [45, 73, 75, 79, 80, 84, 86, 95, 96, 118],
e.g. if several uraemic toxins of similar origin were studied
or if the same solute was assessed in several different
studies. The two hard outcome studies that we retrieved
assessing progression of kidney failure were negative at
primary analysis [89, 90]. Of note, our literature search was
not systematic, but a systematic review and meta-analysis
on the topic a few years ago came to the same conclusions
and classiﬁed the quality of the retrieved papers frommod-
erate to very low [72, 89].
In view of the concern that probiotics might lose their
effect if they do not survive the acidic milieu of the
stomach, encapsulated formulations have been consid-
ered to offer new perspectives [16]. A few studies showed
a decrease in uraemic toxin concentration but were non-
randomized [85, 87, 88]. The only hard outcome study on
encapsulated probiotics was not randomized either and,
as mentioned earlier, the results were negative [89].
The studies in uraemia are scarce, and mostly not ran-
domized, or if randomized, results are often inconsistent.
The number of RCTs in healthy subjects is larger, but here
only urinary excretion and no plasma levels were checked.
Consistent data have been reported on AST-120 as far
as reduction of protein-bound solutes is concerned. A few
small Japanese RCTs of variable quality suggested that
this sorbent could refrain progression of CKD [102–104].
A large RCT could, however, not conﬁrm these promising
results [105].
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In brief, what is needed in this area is well conceived,
sufﬁciently powered, randomized placebo-controlled trials,
performed in comparable groups (e.g. in regard to kidney
function) and under standardized conditions of food intake,
adherence and other inﬂuencing factors. If promising data
are obtained with regard to toxin concentration, these
should be followed by hard outcome studies.
Conclusions
A host of data that have been acquired lately pointing to a
strong bidirectional link between renal failure and the in-
testine, whereby in the intestine, uraemic toxins are gen-
erated which cause inﬂammation and are deleterious to
body functions, while uraemia affects intestinal functions
and protective barriers, which in their turn lead to inﬂam-
mation (Figure 2). Several recent studies deliver proof of
concept of the crosstalk between the intestine and the
uraemic condition. In spite of the availability of a number
of therapeutic options to interfere with this process,
results of clinical trials remain unconvincing, partly due to
the design of the studies and partly to the lack of a hard
outcome evidence base.
Future therapeutic clinical studies in this context should
focus on a more rigid controlled setting, with hard out-
comes and a decrease of target uraemic solutes as
primary endpoints, including a control of compliance and
if possible of dietary elements with potential inﬂuence.
However, ﬁrst we need more insight in the basic mechan-
isms and bacteriological underpinning of the gut–kidney
crosstalk. Maybe single interventions are not efﬁcient
enough, and combination therapies should be considered.
Conﬂict of interest statement. None declared.
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